Guselkumab for the treatment of palmoplantar pustulosis, PMID: 32321322
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial, PMID: 32178766
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial, PMID: 32178765
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial, PMID: 28057360
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial, PMID: 28057361
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial, PMID: 31887225
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial, PMID: 31402114
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial, PMID: 32880909
Guselkumab for the treatment of psoriasis, PMID: 29482382
Guselkumab for the Treatment of Psoriasis, PMID: 29470778
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study, PMID: 31207232
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis, PMID: 33043600
Guselkumab for plaque psoriasis, PMID: 31363311
Guselkumab: A Review in Moderate to Severe Plaque Psoriasis, PMID: 30467781
Guselkumab, PMID: 31643594
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review, PMID: 32427307
[Guselkumab], PMID: 31200928
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials, PMID: 31583255
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial, PMID: 28635018
Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults, PMID: 33251833
Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial, PMID: 31268476
Guselkumab in the treatment of moderate-to-severe plaque psoriasis, PMID: 32314622
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study, PMID: 32665433
Guselkumab, PMID: 29999977
Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial, PMID: 29417135
Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1, PMID: 32660282
Guselkumab for the treatment of moderate-to-severe plaque psoriasis, PMID: 29478344
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis, PMID: 29532693
Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis, PMID: 32173916
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials, PMID: 29799960
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study, PMID: 29893222
Guselkumab for the treatment of psoriasis - evidence to date, PMID: 31391856
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years, PMID: 30124721
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease, PMID: 31389737
Tremfya™ (Guselkumab), PMID: 30888946
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies, PMID: 30417277
A safety evaluation of guselkumab for the treatment of psoriasis, PMID: 29897790
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis, PMID: 31354244
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials, PMID: 31809827
Guselkumab: First Global Approval, PMID: 28819723
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials, PMID: 28639011
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study, PMID: 32910434
Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis, PMID: 29771254
Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment, PMID: 32998185
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics, PMID: 30772098
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS), PMID: 31705526
Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis, PMID: 33488109
Psoriasis Drug Guselkumab Improved Psoriatic Arthritis Symptoms, PMID: 32453367
IL-23 inhibitor guselkumab shows promise for PsA, PMID: 32265523
Guselkumab: Short-term effectiveness and safety in real clinical practice, PMID: 32227659
For research use only. Not for human or drug use.
